TITLE

A randomized trial of the effects of exercise training in Chagas cardiomyopathy

AUTHOR(S)
Lima, Márcia M. O.; Rocha, Manoel Otávio C.; Nunes, Maria Carmo P.; Sousa, Lidiane; Costa, Henrique S.; Alencar, Maria Clara N.; Britto, Raquel R.; Ribeiro, Antonio Luiz P.
PUB. DATE
August 2010
SOURCE
European Journal of Heart Failure;Aug2010, Vol. 12 Issue 8, p866
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aims: The effects of exercise training in chronic heart failure are well established, however, they have not been evaluated in Chagas cardiomyopathy (ChC). We sought to determine the effects of exercise training on functional capacity, health-related quality of life (HQoL), and brain natriuretic peptide (BNP) levels in patients with ChC.
ACCESSION #
52738042

 

Related Articles

  • BATTLESCARRED: NT-proBNP-guided therapy improved mortality in older patients with chronic HF.  // Cardiology Today;Feb2010, Vol. 13 Issue 2, p23 

    The article discusses the BATTLESCARRED research on the efficacy of a hormone-guided treatment strategy guided by N-terminal pro-B-type natriuretic peptide levels in reducing mortality in patients aged 75 years and older with chronic heart failure (HF), with a reference to a study by J....

  • Use of Nesiritide to Treat Acute Decompensated Heart Failure. Hachey, David; Smith, Tony // Critical Care Nurse;Feb2003, Vol. 23 Issue 1, p53 

    Introduces the human B-type natriuretic peptide Natrecor or nesiritide indicated for intravenous treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. Types of natriuretic peptides; Roles of the peptides; Mechanism of action of nesiritide.

  • A natriuretic peptide with hemodynamic benefits in patients with acute decompensated CHF. Dunn, Alisha; Chow, Moses S.S.; Kluger, Jeffrey // Formulary;Feb99, Vol. 34 Issue 2, p123 

    Discusses study findings on the use of the synthetically prepared brain natriuretic peptide (BNP) called nesiritide for the treatment of decompensated congestive heart failure (CHF). Predominant hemodynamic effects of exogenously administered BNP; Incidence of ventricular tachycardia; Most...

  • Neseritide. Caron, Michael F.; White, C. Michael // Formulary;Sep2001, Vol. 36 Issue 9, p639 

    Examines the effects of a brain natriuretic peptide Nesiritide for treating patients with acutely decompensated congestive heart failure. Reduction of pulmonary capillary wedge pressure using nesiritide; Association between nesiritide and arrhythmic events; Need for blood pressure monitoring...

  • Focus on omapatrilat. Song, Jessica C.; White, C. Michael // Formulary;Oct2001, Vol. 36 Issue 10, p698 

    Examines a novel neuval for the treatment of hypertension and heart failure. Inhibition results in elevated natriuretic peptide levels; Dosages of Omapatrilat; Establishment of the efficacy of clinical hypertension trials. INSETS: Background on natriuretic peptides;Formulary considerations.

  • The value of serum N-terminal pro-brain natriuretic peptide levels in the differential diagnosis and follow-up of congestive cardiac failure and respiratory distress due to pulmonary aetiologies in infants and children. Evim, Melike Sezgin; Ucar, Birsen; Kilic, Zübeyir; Colak, Omer // Cardiology in the Young;Jul2010, Vol. 20 Issue 5, p495 

    Objective: We aimed to determine whether N-terminal pro-brain natriuretic peptide can differentiate between cardiac and pulmonary aetiologies of dyspnoea, if N-terminal pro-brain natriuretic peptide can be used for evaluating the effect of treatment in cardiac failure, and for predicting severe...

  • NOBEX and Biocon to Codevelop Oral Peptide for Treating Congestive Heart Failure. Rios, Maribel // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p28 

    Reports that Nobex Corp. and Biocon Ltd. will codevelop an oral formulation of human brain-type natriuretic peptide (hBNP) for the treatment of congestive heart failure. Terms of agreement; Oral bioavailability of hBNP.

  • Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Pitt, Bertram; Latini, Roberto; Maggioni, Aldo P.; Solomon, Scott D.; Smith, Beverly A.; Wright, Melanie; Prescott, Margaret F.; McMurray, John J.V. // European Journal of Heart Failure;Jul2011, Vol. 13 Issue 7, p755 

    Aims We evaluated the influence of concomitant mineralocorticoid receptor antagonists (MRAs) on the safety and neurohumoral effects of a direct renin inhibitor in the ALiskiren Observation of Heart Failure Treatment (ALOFT) study. Methods and results Patients with stable New York Heart...

  • Nesiritide and heart failure. Elliott, William T. // Infectious Disease Alert;Sep2011 Pharmacology Watch, p2 

    The article focuses on a study which examined the safety and efficacy of nesiritide in treating patients with acute heart failure.

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics